Dianthus Therapeutics (NASDAQ:DNTH) Director Simon Read Sells 2,777 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,777 shares of Dianthus Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.55, for a total value of $304,220.35. Following the sale, the director owned 2,777 shares of the company’s stock, valued at approximately $304,220.35. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $108.49 on Wednesday. The stock has a market cap of $5.93 billion, a price-to-earnings ratio of -26.14 and a beta of 1.22. The business has a 50 day simple moving average of $95.71 and a 200 day simple moving average of $81.79. Dianthus Therapeutics, Inc. has a 52 week low of $19.00 and a 52 week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. On average, analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after acquiring an additional 139 shares during the period. First Horizon Corp acquired a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $32,000. Virtus Investment Advisers LLC lifted its position in shares of Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares during the last quarter. Royal Bank of Canada boosted its stake in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DNTH has been the subject of several analyst reports. Truist Financial lifted their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. HC Wainwright boosted their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Finally, Wedbush increased their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $124.27.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright issued an optimistic estimate for Dianthus Therapeutics’ earnings, offering a potential bullish catalyst for DNTH. However, the report did not provide specific revised earnings targets. HC Wainwright Issues Optimistic Estimate for DNTH Earnings
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting period, with a days-to-cover ratio of zero. This indicates little evidence of active short-selling pressure or a potential short squeeze in DNTH.
• Negative Sentiment: Several insiders sold shares around $109 to $111. Senior Vice President Adam M. Veness sold 20,000 shares across transactions on August 7 and August 10 for approximately $2.21 million, reducing his position by roughly 80.8% overall. SEC insider trading filing
• Negative Sentiment: Director Simon Read sold 2,777 shares for about $304,000, cutting his holdings by 50%. Director Anne McGeorge sold 7,750 shares for approximately $845,000, reducing her position by about 86%. The timing and size of these sales could raise concerns because they occurred while the stock was trading near its 12-month high. SEC director trading filing

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.